Simultaneous quantification of multiple biomarker classes from blood is essential for improving diagnostic accuracy, yet current methods remain limited by low multiplexing capacity, reliance on separate instruments and workflows, and inconsistent signal readouts that hinder data integration. Here, we present FluoMag-dCoDe (Fluorescence-coded, Magnetic bead-enhanced digital Co-Detection of multi-analytes), a unified platform that converts diverse analytes into distinct fluorescence-coded DNA templates for multiplexed quantification in a single digital PCR (dPCR) reaction using a universal primer and TaqMan probe set. We demonstrate co-measurement of eight mRNA and three protein immune-response biomarkers in a two-color dPCR format. The platform achieves high quantitative fidelity with minimal cross-interference, showing strong concordance with single-plex RT-qPCR for mRNAs and superior analytical sensitivity to ELISA for proteins – including reliable detection of TRAIL where ELISA failed – from ~ 35 μL fingerstick-compatible blood volumes. By unifying mRNA and protein quantification in a single standardized readout while sustaining robust performance from low blood volumes, FluoMag-dCoDe establishes a scalable approach for high-dimensional biomarker analysis in precision diagnostics.

The authors have declared no competing interest.

This study was funded by the National Institutes of Health (R01CA260628, R33CA272321, R01AI183336, and R01AI181217).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.